Page last updated: 2024-11-01

nifenazone and Cardiomyopathies

nifenazone has been researched along with Cardiomyopathies in 1 studies

nifenazone: RN given refers to parent cpd; structure

Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhang, Y1
Li, Y1
Hu, Q1
Xi, Y1
Xing, Z1
Zhang, Z1
Huang, L1
Wu, J1
Liang, K1
Nguyen, TK1
Egranov, SD1
Sun, C1
Zhao, Z1
Hawke, DH1
Li, J1
Sun, D1
Kim, JJ1
Zhang, P1
Cheng, J1
Farida, A1
Hung, MC1
Han, L1
Darabi, R1
Lin, C1
Yang, L1

Other Studies

1 other study available for nifenazone and Cardiomyopathies

ArticleYear
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin.
    Nature cell biology, 2020, Volume: 22, Issue:11

    Topics: Animals; Antipyrine; Cardiomyopathies; Cell Line; Disease Models, Animal; Dystrophin; Enzyme Inhibit

2020